Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical studies for its recombinant COVID-19 vaccine (CHO cell) and recombinant COVID-19 variant vaccine (CHO cell), due to the assessment of low economic and social benefits. The vaccines were approved for clinical trials in China in June 2021 and August 2022, respectively, and were sponsored by the Coalition for Epidemic Preparedness Innovations (CEPI), a Norway-based NGO. Walvax Bio will be in discussions with CEPI for the final cancellation of the funds provided.- Flcube.com
Recent news:
-
Luye Pharma's Shandong Boan Bio Reports 17.5% Revenue Growth in 2024 -
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion -
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials -
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots -
Sanofi's mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
